Leiden University Scholarly Publications

Your Search

Enabled Filters

  • (-) = Dubiel, R.

Search results

  • RSS Feed
(1 - 4 of 4)
Idarucizumab for Dabigatran Reversal - Full Cohort Analysis
Pollack, C.V.; Reilly, P.A.; Ryn, J. van; Eikelboom, J.W.; Glund, S.; Bernstein, R.A.; ... ; Weitz, J.I. 2017
Idarucizumab for Dabigatran Reversal - Full Cohort Analysis
Article / Letter to editor
metadata only
Healthcare resource utilization in patients receiving idarucizumab for reversal of dabigatran anticoagulation due to major bleeding, urgent surgery, or procedural interventions: interim results from the RE-VERSE AD (TM) study
Pollack, C.V.; Bernstein, R.; Dubiel, R.; Reilly, P.; Gruenenfelder, F.; Huisman, M.V.; ... ; Weitz, J.I. 2017
Healthcare resource utilization in patients receiving idarucizumab for reversal of dabigatran anticoagulation due to major bleeding, urgent surgery, or procedural interventions: interim results from the RE-VERSE AD (TM) study
Article / Letter to editor
metadata only
Idarucizumab for Dabigatran Reversal
Pollack Jr, C.V.; Reilly, P.A.; Eikelboom, J.; Glund, S.; Verhamme, P.; Bernstein, R.A.; ... ; Weitz, J.I. 2015
Idarucizumab for Dabigatran Reversal
Article / Letter to editor
metadata only
Design and rationale for RE-VERSE AD: A phase 3 study of idarucizumab, a specific reversal agent for dabigatran
Pollack, C.V.; Reilly, P.A.; Bernstein, R.; Dubiel, R.; Eikelboom, J.; Glund, S.; ... ; Weitz, J.I. 2015
Design and rationale for RE-VERSE AD: A phase 3 study of idarucizumab, a specific reversal agent for dabigatran
Article / Letter to editor
metadata only